Today: Today, Founders Capital Management LLC Sold shares of Gilead Sciences Inc. (GILD)

Today, Founders Capital Management LLC Sold shares of Gilead Sciences Inc. (GILD)

Founders Capital Management LLC decreased its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 9.3% during the third quarter, Holdings Channel reports. The firm owned 18,066 shares of the biopharmaceutical company’s stock after selling 1,850 shares during the period. Founders Capital Management LLC’s holdings in Gilead Sciences were worth $1,429,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. Lawson Kroeker Investment Management Inc. NE increased its position in Gilead Sciences by 40.2% in the second quarter. Lawson Kroeker Investment Management Inc. NE now owns 104,354 shares of the biopharmaceutical company’s stock valued at $8,705,000 after buying an additional 29,944 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in Gilead Sciences by 9.1% in the second quarter. Kistler Tiffany Companies LLC now owns 3,891 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 324 shares during the last quarter. Fulton Bank N.A. increased its position in Gilead Sciences by 7.2% in the second quarter. Fulton Bank N.A. now owns 43,863 shares of the biopharmaceutical company’s stock valued at $3,659,000 after buying an additional 2,947 shares during the last quarter. Nexus Investment Management Inc. increased its position in Gilead Sciences by 1.5% in the second quarter. Nexus Investment Management Inc. now owns 201,841 shares of the biopharmaceutical company’s stock valued at $16,838,000 after buying an additional 2,991 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its position in Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock valued at $181,075,000 after buying an additional 8,430 shares during the last quarter. Institutional investors own 73.59% of the company’s stock.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.19% on Monday, hitting $74.54. The stock’s 50 day moving average is $74.54 and its 200-day moving average is $80.07. Gilead Sciences Inc. has a 1-year low of $71.39 and a 1-year high of $107.38. The firm has a market capitalization of $98.20 billion, a price-to-earnings ratio of 6.89 and a beta of 1.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the consensus estimate of $2.87 by $0.12. The firm had revenue of $7.40 billion for the quarter, compared to analyst estimates of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The company’s quarterly revenue was down 9.6% on a year-over-year basis. During the same period last year, the firm earned $3.22 EPS. Equities analysts expect that Gilead Sciences Inc. will post $11.47 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.53%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.

Several research analysts have weighed in on the company. Berenberg Bank began coverage on Gilead Sciences in a research note on Thursday, September 22nd. They issued a “buy” rating for the company. Jefferies Group reiterated a “buy” rating and set a $91.00 target price on shares of Gilead Sciences in a research report on Thursday, September 22nd. Piper Jaffray Cos. set a $108.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, September 22nd. Leerink Swann set a $112.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, September 22nd. Finally, Gabelli reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 23rd. Ten analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $97.90.

In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the transaction, the insider now owns 3,287,810 shares of the company’s stock, valued at $254,739,518.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director John W. Madigan sold 105,000 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment